{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:02:19Z","timestamp":1760608939715},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,6,17]],"date-time":"2016-06-17T00:00:00Z","timestamp":1466121600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s11940-016-0419-0","type":"journal-article","created":{"date-parts":[[2016,6,17]],"date-time":"2016-06-17T05:30:02Z","timestamp":1466141402000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Management of Neurologic Manifestations in Patients with Liver Disease"],"prefix":"10.1007","volume":"18","author":[{"given":"Jos\u00e9 M.","family":"Ferro","sequence":"first","affiliation":[]},{"given":"Pedro","family":"Viana","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcia","family":"Santos","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,6,17]]},"reference":[{"key":"419_CR1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2012.12.005","volume":"58","author":"M Blachier","year":"2013","unstructured":"Blachier M, Leleu H, Peck-Radosavljevic M, Valla D-C, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58:593\u2013608.","journal-title":"J Hepatol"},{"key":"419_CR2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11910-014-0487-z","volume":"14","author":"JM Ferro","year":"2014","unstructured":"Ferro JM, Oliveira S. Neurologic manifestations of gastrointestinal and liver diseases. Curr Neurol Neurosci Rep. 2014;14:487.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"419_CR3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1586\/17474124.2014.858598","volume":"8","author":"JP Sturgeon","year":"2014","unstructured":"Sturgeon JP, Shawcross DL. Recent insights into the pathogenesis of hepatic encephalopathy and treatments. Expert Rev Gastroenterol Hepatol. 2014;8:83\u2013100.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"419_CR4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.abb.2013.02.010","volume":"536","author":"N Palomero-Gallagher","year":"2013","unstructured":"Palomero-Gallagher N, Zilles K. Neurotransmitter receptor alterations in hepatic encephalopathy: a review. Arch Biochem Biophys. 2013;536:109\u201321.","journal-title":"Arch Biochem Biophys"},{"key":"419_CR5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27210","volume":"60","author":"H Vilstrup","year":"2014","unstructured":"Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60:715\u201335. The most recently published guidelines with substantial discussion and levels of evidence of different treatment options for hepatic encephalopathy in chronic liver disease.","journal-title":"Hepatology"},{"key":"419_CR6","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1056\/NEJMra1208937","volume":"369","author":"W Bernal","year":"2013","unstructured":"Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369:2525\u201334. Clear and concise review on the management of acute liver failure.","journal-title":"N Engl J Med"},{"key":"419_CR7","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/hep.20703","volume":"41","author":"J Polson","year":"2005","unstructured":"Polson J, Lee WM. AASLD position paper: the management of acute liver failure: update 2011. Hepatology. 2005;41:1179\u201397. Most recent practice recommendations for the management of acute liver failure, by the American Association for The Study of Liver Disease.","journal-title":"Hepatology"},{"key":"419_CR8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/B978-0-7020-4087-0.00044-9","volume":"120","author":"S Datar","year":"2014","unstructured":"Datar S, Wijdicks EFM. Neurologic manifestations of acute liver failure. Handb Clin Neurol. 2014;120:645\u201359.","journal-title":"Handb Clin Neurol"},{"key":"419_CR9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1067\/j.cpradiol.2015.03.004","volume":"44","author":"B Sureka","year":"2015","unstructured":"Sureka B, Bansal K, Patidar Y, Rajesh S, Mukund A, et al. Neurologic manifestations of chronic liver disease and liver cirrhosis. Curr Probl Diagn Radiol. 2015;44:449\u201361. Comprehensive review of the neuroimaging abnormalities related to chronic liver disease patients.","journal-title":"Curr Probl Diagn Radiol"},{"key":"419_CR10","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/CCM.0000000000000144","volume":"42","author":"CJ Karvellas","year":"2014","unstructured":"Karvellas CJ, Fix OK, Battenhouse H, Durkalski V, Sanders C, et al. Outcomes and complications of intracranial pressure monitoring in acute liver failure: a retrospective cohort study. Crit Care Med. 2014;42:1157\u201367.","journal-title":"Crit Care Med"},{"key":"419_CR11","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.neuint.2011.09.006","volume":"60","author":"J Vaquero","year":"2012","unstructured":"Vaquero J. Therapeutic hypothermia in the management of acute liver failure. Neurochem Int. 2012;60:723\u201335.","journal-title":"Neurochem Int"},{"key":"419_CR12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jhep.2004.03.017","volume":"41","author":"V Bhatia","year":"2004","unstructured":"Bhatia V, Batra Y, Acharya SK. Prophylactic phenytoin does not improve cerebral edema or survival in acute liver failure\u2014a controlled clinical trial. J Hepatol. 2004;41:89\u201396.","journal-title":"J Hepatol"},{"key":"419_CR13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1572-0241.2001.03552.x","volume":"96","author":"JF Cadranel","year":"2001","unstructured":"Cadranel JF, Lebiez E, Di Martino V, Bernard B, El Koury S, et al. Focal neurological signs in hepatic encephalopathy in cirrhotic patients: an underestimated entity? Am J Gastroenterol. 2001;96:515\u20138.","journal-title":"Am J Gastroenterol"},{"key":"419_CR14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jstrokecerebrovasdis.2010.01.011","volume":"20","author":"Y Yamamoto","year":"2011","unstructured":"Yamamoto Y, Nishiyama Y, Katsura K-I, Yamazaki M, Katayama Y. Hepatic encephalopathy with reversible focal neurologic signs resembling acute stroke: case report. J Stroke Cerebrovasc Dis. 2011;20:377\u201380.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"Suppl 2","key":"419_CR15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00586-013-2828-z","volume":"23","author":"S Ben Amor","year":"2014","unstructured":"Ben Amor S, Saied MZ, Harzallah MS, Benammou S. Hepatic myelopathy with spastic paraparesis: report of two cases and review of the literature. Eur Spine J. 2014;23 Suppl 2:167\u201371.","journal-title":"Eur Spine J"},{"key":"419_CR16","doi-asserted-by":"publisher","unstructured":"Kori P, Sahu R, Jaiswal A, Shukla R. Hepatic myelopathy: an unusual neurological complication of chronic liver disease presenting as quadriparesis. BMJ Case Rep. 2013. doi: 10.1136\/bcr-2013-009078","DOI":"10.1136\/bcr-2013-009078"},{"key":"419_CR17","doi-asserted-by":"crossref","first-page":"735906","DOI":"10.1155\/2012\/735906","volume":"2012","author":"M Premkumar","year":"2012","unstructured":"Premkumar M, Bagchi A, Kapoor N, Gupta A, Maurya G, et al. Hepatic myelopathy in a patient with decompensated alcoholic cirrhosis and portal colopathy. Case Reports Hepatol. 2012;2012:735906.","journal-title":"Case Reports Hepatol"},{"key":"419_CR18","first-page":"1352","volume":"33","author":"M Cui","year":"2012","unstructured":"Cui M, Zhang X, Mu F. Hepatic myelopathy associated with advanced liver cirrhosis. Saudi Med J. 2012;33:1352\u20134.","journal-title":"Saudi Med J"},{"key":"419_CR19","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/lt.22149","volume":"16","author":"U Baccarani","year":"2010","unstructured":"Baccarani U, Zola E, Adani GL, Cavalletti M, Schiff S, et al. Reversal of hepatic myelopathy after liver transplantation: fifteen plus one. Liver Transpl. 2010;16:1336\u20137.","journal-title":"Liver Transpl"},{"key":"419_CR20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1478-3231.2009.02030.x","volume":"29","author":"JM Guerit","year":"2009","unstructured":"Guerit JM, Amantini A, Fischer C, Kaplan PW, Mecarelli O, et al. Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines. Liver Int. 2009;29:789\u201396. Practice recommendations for the neurophysiological investigation of hepatic encephalopathy related to chronic liver disease.","journal-title":"Liver Int"},{"key":"419_CR21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/hep.1840090231","volume":"9","author":"HO Conn","year":"1989","unstructured":"Conn HO, Levy LL. The nonspecificity of electroencephalographic triphasic waves: the emperor defrocked. Hepatology. 1989;9:337\u20138.","journal-title":"Hepatology"},{"key":"419_CR22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11011-011-9242-1","volume":"26","author":"MM Lauridsen","year":"2011","unstructured":"Lauridsen MM, Jepsen P, Vilstrup H. Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy: a comparative study of 154 patients with liver disease. Metab Brain Dis. 2011;26:135\u20139.","journal-title":"Metab Brain Dis"},{"key":"419_CR23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1478-3231.2009.02009.x","volume":"29","author":"C Randolph","year":"2009","unstructured":"Randolph C, Hilsabeck R, Kato A, Kharbanda P, Li YY, et al. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int. 2009;29:629\u201335. Practice guidelines with extensive overview of neuropsychological tests used in hepatic encephalopathy related to chronic liver disease.","journal-title":"Liver Int"},{"key":"419_CR24","doi-asserted-by":"crossref","first-page":"E92","DOI":"10.1111\/hepr.12227","volume":"44","author":"A Mina","year":"2014","unstructured":"Mina A, Moran S, Ortiz-Olvera N, Mera R, Uribe M. Prevalence of minimal hepatic encephalopathy and quality of life in patients with decompensated cirrhosis. Hepatol Res. 2014;44:E92\u20139.","journal-title":"Hepatol Res"},{"key":"419_CR25","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1136\/bmj.38048.506134.EE","volume":"328","author":"B Als-Nielsen","year":"2004","unstructured":"Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ. 2004;328:1046.","journal-title":"BMJ"},{"key":"419_CR26","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/BF01295920","volume":"38","author":"C Camm\u00e0","year":"1993","unstructured":"Camm\u00e0 C, Fiorello F, Tin\u00e8 F, Marchesini G, Fabbri A, et al. Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis. Dig Dis Sci. 1993;38:916\u201322.","journal-title":"Dig Dis Sci"},{"key":"419_CR27","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1001\/jamainternmed.2014.4746","volume":"174","author":"RS Rahimi","year":"2014","unstructured":"Rahimi RS, Singal AG, Cuthbert JA, Rockey DC. Lactulose vs polyethylene glycol 3350\u2014electrolyte solution for treatment of overt hepatic encephalopathy. JAMA Intern Med. 2014;174:1727.","journal-title":"JAMA Intern Med"},{"key":"419_CR28","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3748\/wjg.v18.i8.767","volume":"18","author":"KM Eltawil","year":"2012","unstructured":"Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol. 2012;18:767\u201377.","journal-title":"World J Gastroenterol"},{"key":"419_CR29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/apt.12803","volume":"40","author":"N Kimer","year":"2014","unstructured":"Kimer N, Krag A, M\u00f8ller S, Bendtsen F, Gluud LL. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther. 2014;40:123\u201332.","journal-title":"Aliment Pharmacol Ther"},{"key":"419_CR30","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","volume":"362","author":"NM Bass","year":"2010","unstructured":"Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071\u201381.","journal-title":"N Engl J Med"},{"key":"419_CR31","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/apt.13122","volume":"41","author":"G-Q Zhu","year":"2015","unstructured":"Zhu G-Q, Shi K-Q, Huang S, Wang L-R, Lin Y-Q, et al. Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy. Aliment Pharmacol Ther. 2015;41:624\u201335.","journal-title":"Aliment Pharmacol Ther"},{"key":"419_CR32","doi-asserted-by":"crossref","unstructured":"Gluud L, Dam G, Borre M, Les I. Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. J Nutr. 2013;143(8):1263\u20138.","DOI":"10.3945\/jn.113.174375"},{"key":"419_CR33","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/jgh.12142","volume":"28","author":"M Bai","year":"2013","unstructured":"Bai M, Yang Z, Qi X, Fan D, Han G. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2013;28:783\u201392.","journal-title":"J Gastroenterol Hepatol"},{"key":"419_CR34","first-page":"666","volume":"21","author":"S Abid","year":"2011","unstructured":"Abid S, Jafri W, Mumtaz K, Islam M, Abbas Z, et al. Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy. J Coll Physicians Surg Pak. 2011;21:666\u201371.","journal-title":"J Coll Physicians Surg Pak"},{"key":"419_CR35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4103\/1319-3767.136975","volume":"20","author":"K Sharma","year":"2014","unstructured":"Sharma K, Pant S, Misra S, Dwivedi M, Misra A, et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi J Gastroenterol. 2014;20:225\u201332.","journal-title":"Saudi J Gastroenterol"},{"key":"419_CR36","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/j.1872-034X.2012.01015.x","volume":"42","author":"K Holte","year":"2012","unstructured":"Holte K, Krag A, Gluud LL. Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy. Hepatol Res. 2012;42:1008\u201315.","journal-title":"Hepatol Res"},{"key":"419_CR37","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1665-2681(19)31323-7","volume":"12","author":"Q Jiang","year":"2013","unstructured":"Jiang Q, Jiang G, Shi K, Cai H, Wang Y, et al. Oral acetyl-L-carnitine treatment in hepatic encephalopathy: view of evidence-based medicine. Ann Hepatol. 2013;12:803\u20139.","journal-title":"Ann Hepatol"},{"key":"419_CR38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11011-011-9260-z","volume":"26","author":"M Malaguarnera","year":"2011","unstructured":"Malaguarnera M, Vacante M, Motta M, Giordano M, Malaguarnera G, et al. Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial. Metab Brain Dis. 2011;26:281\u20139.","journal-title":"Metab Brain Dis"},{"key":"419_CR39","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/MEG.0b013e32835afaa5","volume":"25","author":"T Burkard","year":"2013","unstructured":"Burkard T, Biedermann A, Herold C, Dietlein M, Rauch M, et al. Treatment with a potassium-iron-phosphate-citrate complex improves PSE scores and quality of life in patients with minimal hepatic encephalopathy: a multicenter, randomized, placebo-controlled, double-blind clinical trial. Eur J Gastroenterol Hepatol. 2013;25:352\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"419_CR40","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.jhep.2013.07.020","volume":"59","author":"M Simon-Talero","year":"2013","unstructured":"Simon-Talero M, Garcia-Martinez R, Torrens M, Augustin S, Gomez S, et al. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J Hepatol. 2013;59:1184\u201392.","journal-title":"J Hepatol"},{"key":"419_CR41","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/hep.26611","volume":"59","author":"DC Rockey","year":"2014","unstructured":"Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RSJ, et al. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology. 2014;59:1073\u201383.","journal-title":"Hepatology"},{"key":"419_CR42","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1478-3231.2011.02698.x","volume":"32","author":"G Wright","year":"2012","unstructured":"Wright G, Vairappan B, Stadlbauer V, Mookerjee RP, Davies NA, et al. Reduction in hyperammonaemia by ornithine phenylacetate prevents lipopolysaccharide-induced brain edema and coma in cirrhotic rats. Liver Int. 2012;32:410\u20139.","journal-title":"Liver Int"},{"key":"419_CR43","first-page":"CD003047","volume":"2","author":"AE Junker","year":"2014","unstructured":"Junker AE, Als-Nielsen B, Gluud C, Gluud LL. Dopamine agents for hepatic encephalopathy. Cochrane Database Syst Rev. 2014;2:CD003047.","journal-title":"Cochrane Database Syst Rev"},{"key":"419_CR44","doi-asserted-by":"crossref","first-page":"e49279","DOI":"10.1371\/journal.pone.0049279","volume":"7","author":"J Ampuero","year":"2012","unstructured":"Ampuero J, Ranchal I, Nunez D, Diaz-Herrero M del M, Maraver M, et al. Metformin inhibits glutaminase activity and protects against hepatic encephalopathy. PLoS One. 2012;7:e49279.","journal-title":"PLoS One"},{"key":"419_CR45","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/MCO.0000000000000084","volume":"17","author":"P Amodio","year":"2014","unstructured":"Amodio P, Canesso F, Montagnese S. Dietary management of hepatic encephalopathy revisited. Curr Opin Clin Nutr Metab Care. 2014;17:448\u201352.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"419_CR46","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/hep.26370","volume":"58","author":"P Amodio","year":"2013","unstructured":"Amodio P, Bemeur C, Butterworth R, Cordoba J, Kato A, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology. 2013;58:325\u201336. Guidelines for nutritional management of hepatic encephalopathy in cirrhosis patients.","journal-title":"Hepatology"},{"key":"419_CR47","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1111\/apt.12771","volume":"39","author":"J An","year":"2014","unstructured":"An J, Kim KW, Han S, Lee J, Lim Y-S. Improvement in survival associated with embolisation of spontaneous portosystemic shunt in patients with recurrent hepatic encephalopathy. Aliment Pharmacol Ther. 2014;39:1418\u201326.","journal-title":"Aliment Pharmacol Ther"},{"key":"419_CR48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/lt.22197","volume":"17","author":"R Garc\u00eda-Mart\u00ednez","year":"2011","unstructured":"Garc\u00eda-Mart\u00ednez R, Rovira A, Alonso J, Jacas C, Sim\u00f3n-Talero M, et al. hepatic encephalopathy is associated with posttransplant cognitive function and brain volume. Liver Transplant. 2011;17:38\u201346.","journal-title":"Liver Transplant"},{"key":"419_CR49","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1053\/j.gastro.2010.02.015","volume":"138","author":"JS Bajaj","year":"2010","unstructured":"Bajaj JS, Schubert CM, Heuman DM, Wade JB, Gibson DP, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology. 2010;138:2332\u201340.","journal-title":"Gastroenterology"},{"key":"419_CR50","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/archneur.60.4.521","volume":"60","author":"PR Burkhard","year":"2003","unstructured":"Burkhard PR, Delavelle J, Du Pasquier R, Spahr L. Chronic parkinsonism associated with cirrhosis: a distinct subset of acquired hepatocerebral degeneration. Arch Neurol. 2003;60:521\u20138.","journal-title":"Arch Neurol"},{"key":"419_CR51","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jhep.2012.11.043","volume":"58","author":"AB Tryc","year":"2013","unstructured":"Tryc AB, Goldbecker A, Berding G, Rumke S, Afshar K, et al. Cirrhosis-related Parkinsonism: prevalence, mechanisms and response to treatments. J Hepatol. 2013;58:698\u2013705.","journal-title":"J Hepatol"},{"key":"419_CR52","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11011-012-9341-7","volume":"28","author":"RF Butterworth","year":"2013","unstructured":"Butterworth RF. Parkinsonism in cirrhosis: pathogenesis and current therapeutic options. Metab Brain Dis. 2013;28:261\u20137.","journal-title":"Metab Brain Dis"},{"key":"419_CR53","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/B978-0-444-52014-2.00011-2","volume":"100","author":"W Meissner","year":"2011","unstructured":"Meissner W, Tison F. Acquired hepatocerebral degeneration. Handb Clin Neurol. 2011;100:193\u20137. Review of the most frequent clinical findings and treatment options for acquired hepatocerebral degeneration.","journal-title":"Handb Clin Neurol"},{"key":"419_CR54","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10072-013-1458-x","volume":"35","author":"E Maffeo","year":"2014","unstructured":"Maffeo E, Montuschi A, Stura G, Giordana MT. Chronic acquired hepatocerebral degeneration, pallidal T1 MRI hyperintensity and manganese in a series of cirrhotic patients. Neurol Sci. 2014;35:523\u201330.","journal-title":"Neurol Sci"},{"key":"419_CR55","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11011-013-9478-z","volume":"29","author":"V Mileti\u0107","year":"2014","unstructured":"Mileti\u0107 V, Ozreti\u0107 D, Relja M. Parkinsonian syndrome and ataxia as a presenting finding of acquired hepatocerebral degeneration. Metab Brain Dis. 2014;29:207\u20139.","journal-title":"Metab Brain Dis"},{"key":"419_CR56","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/archneurol.2011.771","volume":"69","author":"SR Criswell","year":"2012","unstructured":"Criswell SR, Perlmutter JS, Crippin JS, Tom O, Racette BA. Reduced uptake of FDOPA PET in end-stage liver disease with elevated manganese levels. Arch Neurol. 2012;69:394\u20137.","journal-title":"Arch Neurol"},{"key":"419_CR57","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.clineuro.2012.03.032","volume":"114","author":"K Ishii","year":"2012","unstructured":"Ishii K, Shioya A, Fukuda K, Mori K, Tamaoka A. Acquired hepatocerebral degeneration with middle cerebellar peduncles lesions: case report and review of the literature. Clin Neurol Neurosurg. 2012;114:1361\u20134.","journal-title":"Clin Neurol Neurosurg"},{"key":"419_CR58","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/mds.21957","volume":"23","author":"HK Park","year":"2008","unstructured":"Park HK, Kim SM, Choi CG, Lee MC, Chung SJ. Effect of trientine on manganese intoxication in a patient with acquired hepatocerebral degeneration. Mov Disord. 2008;23:768\u201370.","journal-title":"Mov Disord"},{"key":"419_CR59","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1034\/j.1600-0404.2002.01230.x","volume":"106","author":"Y Ueki","year":"2002","unstructured":"Ueki Y, Isozaki E, Miyazaki Y, Koide R, Shimizu T, et al. Clinical and neuroradiological improvement in chronic acquired hepatocerebral degeneration after branched-chain amino acid therapy. Acta Neurol Scand. 2002;106:113\u20136.","journal-title":"Acta Neurol Scand"},{"key":"419_CR60","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1432-2277.2002.tb00150.x","volume":"15","author":"F Lazeyras","year":"2002","unstructured":"Lazeyras F, Spahr L, DuPasquier R, Delavelle J, Burkhard P, et al. Persistence of mild parkinsonism 4 months after liver transplantation in patients with preoperative minimal hepatic encephalopathy: a study on neuroradiological and blood manganese changes. Transpl Int. 2002;15:188\u201395.","journal-title":"Transpl Int"},{"key":"419_CR61","doi-asserted-by":"crossref","unstructured":"Hess CW, Saunders-Pullman R. Movement disorders and alcohol misuse. Addict Biol. 2006;11(2):117\u201325.","DOI":"10.1111\/j.1369-1600.2006.00017.x"},{"key":"419_CR62","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/B978-0-7020-4086-3.00027-8","volume":"119","author":"JJ Asconap\u00e9","year":"2014","unstructured":"Asconap\u00e9 JJ. Use of antiepileptic drugs in hepatic and renal disease. Handb Clin Neurol. 2014;119:417\u201332. Review of pharmacokinetic aspects and safety issues for the use of antiepileptic drugs in patients with hepatic disease.","journal-title":"Handb Clin Neurol"},{"key":"419_CR63","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.3748\/wjg.v20.i13.3410","volume":"20","author":"LE Adinolfi","year":"2014","unstructured":"Adinolfi LE, Zampino R, Restivo L, Lonardo A, Guerrera B, et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol. 2014;20:3410\u20137.","journal-title":"World J Gastroenterol"},{"key":"419_CR64","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/apt.12391","volume":"38","author":"C-S Hsu","year":"2013","unstructured":"Hsu C-S, Kao J-H, Chao Y-C, Lin HH, Fan Y-C, et al. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Aliment Pharmacol Ther. 2013;38:415\u201323.","journal-title":"Aliment Pharmacol Ther"},{"key":"419_CR65","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1161\/STROKEAHA.115.008582","volume":"46","author":"P Yan","year":"2015","unstructured":"Yan P, Zhu A, Liao F, Xiao Q, Kraft AW, et al. Minocycline reduces spontaneous hemorrhage in mouse models of cerebral amyloid angiopathy. Stroke. 2015;46:1633\u201340.","journal-title":"Stroke"},{"key":"419_CR66","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jocn.2012.03.029","volume":"20","author":"M Mehndiratta","year":"2013","unstructured":"Mehndiratta M, Pandey S, Nayak R, Saran RK. Acute onset distal symmetrical vasculitic polyneuropathy associated with acute hepatitis B. J Clin Neurosci. 2013;20:331\u20132.","journal-title":"J Clin Neurosci"},{"key":"419_CR67","doi-asserted-by":"crossref","first-page":"236148","DOI":"10.1155\/2012\/236148","volume":"2012","author":"S Monaco","year":"2012","unstructured":"Monaco S, Ferrari S, Gajofatto A, Zanusso G, Mariotto S. HCV-related nervous system disorders. Clin Dev Immunol. 2012;2012:236148.","journal-title":"Clin Dev Immunol"},{"key":"419_CR68","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S1665-2681(19)31434-6","volume":"11","author":"MCM Cheung","year":"2012","unstructured":"Cheung MCM, Maguire J, Carey I, Wendon J, Agarwal K. Review of the neurological manifestations of hepatitis E infection. Ann Hepatol. 2012;11:618\u201322.","journal-title":"Ann Hepatol"},{"key":"419_CR69","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.neurol.2007.09.003","volume":"164","author":"B Moutawakil El","year":"2008","unstructured":"El Moutawakil B, Bourezgui M, Rafai MA, Sibai M, Boulaajaj FZ, et al. Acute disseminated encephalomyelitis associated with hepatitis A virus infection. Rev Neurol (Paris). 2008;164:852\u20134.","journal-title":"Rev Neurol (Paris)"},{"key":"419_CR70","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/B978-0-444-53488-0.00031-6","volume":"123","author":"J Sellner","year":"2014","unstructured":"Sellner J, Steiner I. Neurologic complications of hepatic viruses. Handb Clin Neurol. 2014;123:647\u201361.","journal-title":"Handb Clin Neurol"},{"key":"419_CR71","doi-asserted-by":"crossref","unstructured":"Mengel AM, Stenzel W, Meisel A, B\u00fcning C. Hepatitis E induced severe myositis. Muscle Nerve. Published Online First: 29 October 2015.","DOI":"10.1002\/mus.24959"},{"key":"419_CR72","doi-asserted-by":"crossref","unstructured":"Perrin HB, Cintas P, Abravanel F, G\u00e9rolami R, d\u2019Alteroche L, et al. Neurologic disorders in immunocompetent patients with autochthonous acute hepatitis E. Emerg Infect Dis. 2015;21(11):1928\u201334.","DOI":"10.3201\/eid2111.141789"},{"key":"419_CR73","volume-title":"Extra-hepatic manifestations associated with hepatitis E virus infection: a comprehensive review of the literature","author":"F Bazerbachi","year":"2015","unstructured":"Bazerbachi F, Haffar S, Garg SK, Lake JR. Extra-hepatic manifestations associated with hepatitis E virus infection: a comprehensive review of the literature. 2015."},{"key":"419_CR74","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1620\/tjem.236.263","volume":"236","author":"Y Yazaki","year":"2015","unstructured":"Yazaki Y, Sugawara K, Honda M, Ohnishi H, Nagashima S, et al. Characteristics of 20 patients with autochthonous acute hepatitis E in Hokkaido, Japan: first report of bilateral facial palsy following the infection with genotype 4 hepatitis E virus. Tohoku J Exp Med. 2015;236:263\u201371.","journal-title":"Tohoku J Exp Med"},{"key":"419_CR75","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jcv.2014.01.026","volume":"60","author":"A Deroux","year":"2014","unstructured":"Deroux A, Brion JP, Hyerle L, Belbezier A, Vaillant M, et al. Association between hepatitis E and neurological disorders: two case studies and literature review. J Clin Virol. 2014;60:60\u20132.","journal-title":"J Clin Virol"},{"key":"419_CR76","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.pediatrneurol.2014.04.017","volume":"51","author":"JP Domingos","year":"2014","unstructured":"Domingos JP, Garrido C, Moreira Silva H, Monteiro C, Silva ES, et al. Chronic inflammatory demyelinating polyneuropathy associated with autoimmune hepatitis. Pediatr Neurol. 2014;51:e13\u20134.","journal-title":"Pediatr Neurol"},{"key":"419_CR77","doi-asserted-by":"crossref","unstructured":"Park KH, Sohn SY, Sung JJ, Lee KW, Hong YH. Subacute sensorimotor polyneuropathy associated with autoimmune hepatitis. J Clin Neurol. 2016;12(1):123\u20135.","DOI":"10.3988\/jcn.2016.12.1.123"},{"key":"419_CR78","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.amjmed.2015.02.017","volume":"128","author":"P Cacoub","year":"2015","unstructured":"Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D. Cryoglobulinemia vasculitis. Am J Med. 2015;128:950\u20135.","journal-title":"Am J Med"},{"key":"419_CR79","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/annrheumdis-2013-203883","volume":"73","author":"P Cacoub","year":"2014","unstructured":"Cacoub P, Terrier B, Saadoun D. Hepatitis C virus-induced vasculitis: therapeutic options. Ann Rheum Dis. 2014;73:24\u201330. Review of treatment options for hepatitis C virus-induced vasculitis.","journal-title":"Ann Rheum Dis"},{"key":"419_CR80","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/art.34322","volume":"64","author":"MC Sneller","year":"2012","unstructured":"Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:835\u201342.","journal-title":"Arthritis Rheum"},{"key":"419_CR81","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.34331","volume":"64","author":"S Vita De","year":"2012","unstructured":"De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:843\u201353.","journal-title":"Arthritis Rheum"},{"key":"419_CR82","first-page":"CD010404","volume":"12","author":"TJ Benstead","year":"2014","unstructured":"Benstead TJ, Chalk CH, Parks NE. Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection. Cochrane Database Syst Rev. 2014;12:CD010404.","journal-title":"Cochrane Database Syst Rev"},{"key":"419_CR83","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/B978-0-7020-4087-0.00046-2","volume":"120","author":"CL Ahrens","year":"2014","unstructured":"Ahrens CL, Manno EM. Neurotoxicity of commonly used hepatic drugs. Handb Clin Neurol. 2014;120:675\u201382. Overview of neurologic complications related to commonly used hepatic drugs.","journal-title":"Handb Clin Neurol"},{"key":"419_CR84","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","volume":"370","author":"KV Kowdley","year":"2014","unstructured":"Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879\u201388.","journal-title":"N Engl J Med"},{"key":"419_CR85","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483\u201393.","journal-title":"N Engl J Med"},{"key":"419_CR86","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","volume":"368","author":"E Lawitz","year":"2013","unstructured":"Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878\u201387.","journal-title":"N Engl J Med"},{"key":"419_CR87","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","volume":"370","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993\u20132001.","journal-title":"N Engl J Med"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-016-0419-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-016-0419-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-016-0419-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T18:08:45Z","timestamp":1718647725000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-016-0419-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,17]]},"references-count":87,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["419"],"URL":"https:\/\/doi.org\/10.1007\/s11940-016-0419-0","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,17]]},"article-number":"37"}}